Factors associated with the use of various medications amongst patients with severe coronary artery disease

Journal of Internal Medicine

Volumn 245, Issue 2, 1999, Pages 143-153

  Herlitz, Johan ^a   Brorsson, B ^b   Werko L ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Council on Technology Assessment in Health Care   (Sweden)

Author keywords

Anti ischaemic drugs; Coronary artery disease; Lipid lowering drugs; Revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; NITRIC ACID DERIVATIVE;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; DRUG PREFERENCE; DRUG UTILIZATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; TREATMENT INDICATION; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SWEDEN;

EID: 0032989036     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.0425f.x     Document Type: Article

References (34)

1. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sörensen S, Ömblus R et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-5.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Scand Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
3. Leape L, Hilborne LH, Park RE, Bernstein SJ, Kamberg CJ, Sherwood M et al. Appropriateness of the use of coronary artery bypass surgery in New York State. JAMA 1993; 269: 753-60.
4. Hilborne LH, Leape LL, Bernstein SJ, Park RE, Fiske ME, Kamberg CJ et al. The appropriateness of use of percutaneous transluminal coronary angioplasty in New York State. JAMA 1993; 269: 761-5.
5. Thadani U, Lipicky RJ. Short- and long-acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994; 8: 611-23.
6. Packer M. Drug therapy: combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989; 320: 709-18.
7. Thadani U, Maranda CR, Amsterdam E, Spaccavento L, Friedman RG, Chernoff R et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120: 353-9.
8. Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993; 72: 1249-56.
9. Opie LH, Sonnenblick EH, Frishman W, Thadani U. Beta-blocking agents. In: Opie LH, ed. Drugs for the Heart, 4th edn. Philadelphia: W.B. Saunders Company, 1995; 1-30.
10. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991; 338: 1036-9.
11. Opie LH, Frishman WH, Thadani U. Calcium channel antagonists (calcium entry blockers). In: Opie LH, ed. Drugs for the Heart, 4th edn. Philadelphia: W.B. Saunders Company, 1995; 50-82.
12. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 1991; 9: 73-87.
13. Bengtson A, Herlitz J, Karlsson T, Brandrup-Wognsen G, Hjalmarson Å. The appropriateness of performing coronary angiography and coronary artery revascularization in a Swedish population. JAMA 1994; 271: 1260-65.
14. Naylor CD, Baigre RS, Goldman BS, Basinski A. Assessment of priority for coronary revascularisation procedures. Lancet 1990; 335: 1070-73.
15. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
16. Ridker PM, Manson JAE, Gaziano JM, Buring JE, Hennekens CH. Low-dose asirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-9.
17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
18. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. for the West of Scotland Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. N Engl J Med 1995; 333: 1301-7.
19. Kjekshus J, Pedersen TR for the Scandinavian Simvastatin Survival Study Group. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-8C.
20. Tobin JN, Wassertheil-Smoller S, Wexler JP, Steingart RM, Budner N, Lense L et al. Sex bias in considering coronary bypass surgery. Ann Intern Med 1987; 107: 19-25.
21. Maynard C, Althouse R, Cerquiera M, Olsufka M, Kennedy JW. Underutilization of thrombolytic therapy in eligible women with acute myocardial infarction. Am J Cardiol 1991; 68: 529-30.
22. Pagley PR, Yarzebski J, Goldberg R, Chen Z, Chiriboga D, Dalen P et al. Gender differences in the treatment of patients with acute myocardial infarction. Arch Intern Med 1993; 153: 625-9.
23. Karlson BW, Hartford M, Herlitz J. Treatment of patients with acute myocardial infarction in relation to gender. Cardiology 1996; 87: 230-34.
24. McGovern PG, Herlitz J, Pankow JS et al. Comparison of medical care and one- and 12-month mortality of hospitalized patients with acute myocardial infarction in Minneapolis-St. Paul, Minnesota, United States of America and Göteborg, Sweden. Am J Cardiol 1997; 80: 557-62.
25. EUROASPIRE Study Group. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82.
26. Pilote L, Califf RM, Sapp S, Miller DP, Mark DB, Weaver WD et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995; 333: 565-72.
27. Roberts SJ, Bateman DN. The use of nitrates, calcium channel blockers and ACE inhibitors in primary care in the Northern Region: a pharmacoepidemiological study. Br J Clin Pharmac 1994; 38: 489-97.
28. Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med 1996; 156: 2553-62.
29. Black N, Langham S, Petticrew M. Coronary revascularisation: why do rates vary geographically in the UK? J Epidemiol Community Health 1995; 49: 408-12.
30. Guidelines. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394-413.
31. Tolins M, Weir EK, Chester E, Pierpont GL. 'Maximal' drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984; 3: 1051-7.
32. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7.
33. Hjalmarson A, Herlitz J, Malek I, Rydén L, Wedin A, Waldenström A et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-7.
34. Beta-Blocker Heart Attack Trial Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707-14.